Perrigo plummeted 13 percent in the premarket Monday after issuing very weak guidance.
Drugmaker Valeant Pharmaceuticals is seeking to appoint Perrigo boss Joseph Papa as its new chief executive, a source familiar with the matter said.
Shares of over-the-counter drugmaker Perrigo sank early Friday after its stock owners rejected a hostile, $26 billion takeover bid from Mylan.
Perrigo prevails in its fight to stay independent as Mylan fails to win approval for its $26 billion takeover bid.
Perrigo CEO Joseph Papa, shares his perspective on Mylan's tender offer for his company which closes on Friday. Papa stands firmly opposed to the sale to Mylan.
Joe Papa, Perrigo chairman & CEO, talks about Mylan's hostile bid for Perrigo and why he wants shareholders to reject the offer.
Perrigo rejected Mylan's $27 billion public offer, saying it substantially undervalues the company.
Mylan shareholders back proposed Perrigo purchase.
Mergers and acquisitions worldwide in the second quarter of 2015 almost matched the record set in the second quarter of 2007.
Teva Pharmaceutical is looking to buy more shares in Mylan, positioning itself for a possible legal challenge to the generics drugmaker.
Perrigo acquires OTC portfolio from GlaxoSmithKline for undisclosed sum.
CNBC's David Faber reports Perrigo will reject Mylan's latest offer.
Mylan on Wednesday sweetened its bid for Perrigo.
CNBC's David Faber reports Mylan is increasing its bid for Mylan.
The "Halftime Report" traders give their trades for the second half.
Perrigo is set to close a huge deal for Omega Pharmaceuticals. Perrigo CEO Joseph Papa, discusses the benefits of the deal, and the company's move to Ireland.
Some of the names on the move ahead of the open.
We're moving into a time of year that’s been difficult for bulls, historically. However, if the market does sell off, Cramer won't cry.
The stock market might be making new all-time highs on almost a daily basis, but that doesn’t mean there isn’t bargain to be had.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.